(2026). Alogliptin-metformin synergy ameliorates diabetes-associated bone loss via modulation of DPP-4 activity and OPG/RANKL signaling. 3 Biotech.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Alogliptin-metformin Synergy Ameliorates Diabetes-associated Bone Loss via Modulation of DPP-4 Activity and OPG/RANKL Signaling."
3 Biotech 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Alogliptin-metformin Synergy Ameliorates Diabetes-associated Bone Loss via Modulation of DPP-4 Activity and OPG/RANKL Signaling."
3 Biotech, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.